CBER: What MedTech Teams Need to Know About FDA Biologics (2026)

Part of our FDA 2026 medical device cybersecurity submission series. For the full overview, start with FDA Cybersecurity Requirements for Medical Devices (2026).

Updated October 26, 2024

The Center for Biologics Evaluation and Research (CBER) is the part of the U.S. Food and Drug Administration that regulates many biologic products, including vaccines, blood and blood components, tissues, and cell and gene therapies. Its job is straightforward: make sure these products meet standards for safety, purity, potency, and effectiveness before and after they reach the market.

For MedTech companies, CBER matters when your product sits at the intersection of device, biologic, software, and connected systems. If your technology supports, delivers, stores, monitors, or integrates with biologic products, you need to understand how CBER thinks about quality, evidence, manufacturing, and postmarket oversight.

Why this matters

For medical device manufacturers, understanding CBER's role is critical when devices interact with biologic products. The stakes are high: compromised device cybersecurity can directly impact the safety, purity, and potency of biologics, leading to patient harm or ineffective treatments. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly mandates that medical devices, regardless of their primary regulatory center, demonstrate adequate cybersecurity measures throughout their total product lifecycle.

This includes ensuring the integrity of data related to biologic products, securing software that controls their administration, and protecting networked systems involved in their storage or monitoring. Compliance extends beyond simply preventing breaches; it involves proactive threat modeling, vulnerability management, and maintaining data integrity, particularly for sensitive biologic information. Relevant standards like ISO 81001-5-1, IEC 62443, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide frameworks for establishing and maintaining secure environments for medical devices, which are equally applicable when those devices interface with CBER-regulated biologics.

What CBER Does

CBER evaluates biologic products and the systems used to develop and manufacture them. That includes reviewing preclinical and clinical data, assessing manufacturing consistency, setting policy, and monitoring safety after approval.

Biologics are different from small-molecule drugs. They are often derived from living sources and can include proteins, nucleic acids, blood products, tissues, and engineered cells. That complexity creates variability, and variability creates regulatory risk. CBER exists to reduce that risk with scientific review and regulatory controls.

CBER also conducts and supports research. That work helps the FDA update its thinking as new technologies move from the lab into clinical use. Areas like gene editing, personalized therapies, and emerging infectious disease response all push CBER to refine policy in real time.

Why Biologics Require a Different Level of Oversight

Biologics are often used in high-risk settings: oncology, autoimmune disease, rare disease, transplantation, and genetic disorders. The margin for error is small. Product quality, sterility, chain of custody, manufacturing controls, and postmarket surveillance all matter.

Unlike conventional pharmaceuticals, biologics can be highly sensitive to process changes. A manufacturing deviation, storage issue, or handling problem can affect safety or performance in ways that are not always obvious. That is why CBER spends so much attention on process controls and evidence, not just end-product claims.

For companies building connected platforms around biologics, this should sound familiar. Cybersecurity failures can also become quality failures. If software affects manufacturing data, product traceability, environmental monitoring, access control, or clinical decision support, regulators will not treat that as an IT side issue.

How CBER Is Organized

CBER includes multiple offices with different responsibilities, from product review to inspections, compliance, epidemiology, and policy. The structure matters because sponsors are rarely dealing with just one regulatory function.

Two offices are especially worth noting:

• The Office of Biostatistics and Epidemiology supports data analysis, statistical review, and evidence interpretation.
• The Office of Compliance and Biologics Quality (OCBQ) focuses on compliance, inspections, and biologics quality systems.

That combination tells you a lot about how CBER operates. The center is not only asking whether a product works. It is also asking whether the evidence is sound, the process is controlled, and the manufacturer can keep it that way.

Leadership inside CBER also works across industry, academia, and other regulators. That collaboration shapes policy and can influence how quickly new technologies move into workable regulatory pathways.

The Scope of CBER’s Work

CBER’s responsibilities go well beyond initial review. The center oversees biologic products across the full lifecycle, from development through postmarket monitoring.

Regulatory Responsibilities

CBER reviews applications, inspects facilities, evaluates manufacturing controls, and monitors safety signals after products are marketed. It also works with international regulators to support consistent standards and broader access to safe biologics.

That lifecycle view should be familiar to medical device manufacturers. The FDA does not want static documentation built for a submission and forgotten after clearance or approval. It expects systems that remain effective as products, threats, suppliers, and clinical use change over time.

That is one reason the FDA’s 18 cybersecurity deliverables for medical device submissions matter so much. The same principle applies in biologics oversight: evidence has to connect to actual controls, and controls have to hold up in practice.

Public Health Contributions

CBER also supports public health during outbreaks, supply disruptions, and safety events involving biologic products. Its scientific and regulatory work helps inform policy, labeling, guidance, and risk communication.

The center’s research function matters here too. CBER does not only review sponsor-generated data. It builds internal expertise so the FDA can evaluate new product categories without relying solely on industry’s framing of the science.

Preparing an FDA submission?

Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. → FDA premarket cybersecurity services

CBER’s Impact on Industry

See also: 8 FDA Cybersecurity Deficiencies, Ranked From Real Letters, FDA IDE Cybersecurity Requirements: 2026, and SBOM Diffing & CVE Correlation Postmarket.

CBER sets the terms for how biologics move from concept to market. That affects timelines, development strategy, manufacturing design, clinical evidence plans, and postmarket obligations.

Safety, Effectiveness, and Trust

When CBER applies rigorous review standards, it increases confidence in approved biologics. That trust matters to patients, clinicians, payers, and investors. It also matters to manufacturers trying to build durable market access instead of chasing a one-time approval milestone.

The impact is easy to see in areas like monoclonal antibodies and advanced therapies. Products such as rituximab and trastuzumab changed cancer treatment, but they only became viable at scale because regulators established clear expectations around evidence, manufacturing quality, and ongoing surveillance.

CBER’s postmarket oversight is just as important. Safety monitoring does not stop once a product is approved. If new risks emerge, the FDA expects companies to detect them, assess them, and respond with discipline.

Innovation, With Guardrails

CBER has also helped open paths for newer treatment models, including cell and gene therapies. A good example is CAR-T therapy, which created new treatment options for certain leukemias and lymphomas.

But innovation is not a free pass. CBER supports new approaches while still demanding evidence, control, and reproducibility. That is the right model for cybersecurity, too. Novel software, AI-enabled tooling, cloud infrastructure, and connected workflows are fine if you can show they are secure, validated where needed, and governed across the lifecycle.

What’s Next for CBER

CBER is dealing with the same pressure every modern regulator faces: more technical products, more software dependence, more data, and less tolerance for failure.

Emerging Challenges

Personalized medicine is one pressure point. Individualized therapies do not fit neatly into older regulatory models, which means CBER has to keep adapting its review approaches without lowering standards.

AI is another. Artificial intelligence in healthcare and medical device cybersecurity is already influencing research, development, manufacturing, and surveillance. The opportunity is real. So is the risk. If AI affects product quality, patient safety, or regulated decision-making, companies should expect close scrutiny.

CBER is also paying attention to data integrity and information flow. Whether the enabling technology is advanced analytics, modern cloud architecture, or distributed records systems, the underlying issue stays the same: can the FDA trust the data and the controls around it?

Strategic Priorities

CBER’s stated priorities include improving regulatory efficiency, supporting scientific innovation, strengthening international coordination, and maintaining a workforce that can evaluate complex technologies.

For industry, the takeaway is practical. Do not treat regulation as a documentation exercise. Build systems that can withstand inspection, change control, postmarket scrutiny, and security testing. If your platform touches biologics operations or patient-facing workflows, cybersecurity belongs inside quality and regulatory planning from the start.

CBER is not just a biologics reviewer. It is part of the larger FDA framework that expects manufacturers to understand how product safety, software risk, data integrity, and operational control fit together.

If your organization is building connected medical technologies that intersect with biologics, that expectation is not theoretical. It will show up in your design controls, your supplier oversight, your submission strategy, and your postmarket obligations. Contact us today for cybersecurity help.

CBER, CDRH, and CDER compared

The center changes who reads the file. It does not change what the file has to contain.

How Blue Goat approaches this

Blue Goat Cyber assists medical device manufacturers in working through the cybersecurity requirements for devices interacting with CBER-regulated biologics. Our focused methodology helps integrate cybersecurity into device design and development, ensuring compliance with FDA expectations. We provide detailed guidance on risk management, vulnerability assessments, and secure software development, tailored to the unique challenges of biologic-adjacent technologies. Our team, composed of experts with CISSP and OSCP certifications, including ex-military red team personnel, brings practical defensive and offensive security experience.

We specialize in preparing accurate and complete cybersecurity documentation for premarket submissions, helping to prevent deficiencies. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Explore our services at Medical Device Penetration Testing to learn how we can secure your innovations.

FAQ

What is CBER?

CBER is the Center for Biologics Evaluation and Research, a part of the FDA. It regulates biologic products including vaccines, blood products, and cell and gene therapies to ensure their safety, purity, potency, and effectiveness.

How does CBER impact medical device cybersecurity?

If a medical device or connected system supports, delivers, or interacts with biologic products, CBER's regulatory focus on quality and control extends to its cybersecurity. Cybersecurity failures impacting manufacturing data, traceability, or decision support are quality issues.

Why is CBER's oversight of biologics so strict?

Biologics are often used in high-risk medical settings and are highly sensitive to process changes. CBER's strict oversight ensures product quality, sterility, and performance are maintained, mitigating risks to patients.

Does CBER only review new biologic products?

No, CBER oversees biologic products across their entire lifecycle. This includes initial review, facility inspections, manufacturing control evaluation, and ongoing postmarket safety monitoring and surveillance.

What role does CBER play in emerging technologies like AI?

CBER scrutinizes emerging technologies like AI when they impact product quality, patient safety, or regulated decision-making for biologics. It focuses on data integrity and the controls surrounding these advanced systems.

What are CBER's strategic priorities?

CBER prioritizes improving regulatory efficiency, supporting scientific innovation, strengthening international coordination, and maintaining a workforce capable of evaluating complex, modern biologic technologies.

Related: Medical Device Cybersecurity: A Complete Lifecycle Guide